Table 1 Patient characteristics and surgicopathological findings in 205 endometrial cancer patients

Age, mean (range)

58 (35–87)

BMI, mean (range)

24.69 (18.20–30.00)

Postmenopausal, n (%)

131 (63.90%)

Treatment

Hysterectomy and bilateral salpingooophorectomy

6 (2.93%)

Sentinel lymphadenectomy

25 (12.20%)

Pelvic lymphadenectomy

131 (63.90%)

Para-aortic lymphadenectomy

39 (19.02%)

diagnostic curettage

4 (4.88%)

Surgical approach

Open surgery

16 (7.80%)

Minimally invasive surgery

185 (90.24%)

Laparoscopy

151 (73.66%)

Robotic

34 (16.59%)

Adjuvant therapy

104 (50.73%)

Radiotherapy

104 (50.73%)

Chemotherapy

84 (40.98%)

Hormonal

12 (5.85%)

2009 FIGO stage, n (%)

Stage IA

102 (49.75%)

Stage IB

21 (10.24%)

Stage II

13 (6.34%)

Stage IIIA

9 (4.39%)

Stage IIIB

7 (3.41%)

Stage IIIC1

36 (17.56%)

Stage IIIC2

7 (3.41%)

Stage IVA

6 (2.93%)

Stage IVB

4 (1.95%)

2009- (convert to) 2023 FIGO

IA-IA1

48

IA-IA2

42

IA-IC

2

IA-IIB

3

IA-IIC

6

IB-IB

10

IB-IIC

11

II-IIA

10

II-IIB

1

II-IIC

3

IIIA-IIIA1

8

IIIA-IIIA2

1

IIIB-IIIB1

7

IIIB-IIIB2

1

IIIC1-IIIC1i

32

IIIC1-IIIC1ii

4

IIIC2-IIIC2i

6

IIIC2-IIIC2ii

1

IVA-IVA

6

IVB-IVB

4

Mean follow-up period

Progression

23(11.22%)

Follow-up Metastatic Site

Bladder mucosa

4

Bowel mucosa

3

Pelvic Lymph nodes

2

Para-aortic lymph nodes

3

Liver

1

Lung

7

Bone

3

Histologic subtype, n (%)

Endometrioid

172 (88.78%)

Non-endometrioid

23 (11.22%)

serous

15 (7.32%)

clear cell carcinoma

8 (3.90%)

Histologic grade, n (%)

Grade 1

90 (43.90%)

Grade 2

52 (25.37%)

Grade 3

63 (30.73%)

LVSI

75 (36.59%)

Myometrial invasion, n (%)

< 50%

61 (29.76%)

≥ 50%

69 (33.66%)

Cervical stroma invasion, n (%)

No

177 (86.34%)

Yes

26 (12.68%)

Pelvic Lymph node metastases, n (%)

No

66 (50.38%)

Yes

65 (49.62%)

Paraaortic lymph node metastases, n (%)

No

32 (82.05%)

Yes

7 (17.95%)